Why A1C Partnered With Etana Biotech

A1C was formerly Sally A1C. The name changed as the business grew from a single product into a metabolic health ecosystem. Sally is the AI inside it.

A1C has partnered with Etana Biotech, a pharmaceutical manufacturer that has made medicine since 2014 across cancer, kidney, heart, and blood sugar care. Doctors in Indonesia have known the name for more than a decade.

The partnership moves three A1C products into the clinical supply channel Etana already operates: the CGM program, A1C Insights, and 0spike.

Why distribution and not product

Building software costs almost nothing now. A competent person with a laptop ships in a week what took a funded team a quarter in 2024.

That collapse moved the value to whatever did not collapse with it. Four things stayed expensive:

• Permission to sell a medical device in a country
• Standing inside a medical system, earned over years
• Access to capital that is legally closed to you
• Revenue from customers who pay regardless of narrative

None of those compress. None can be prompted into existence. They are the durable moats left in consumer health, and this partnership secures the first two in Indonesia.

What the partnership changes

It changes where A1C is available. Today it is an app store listing and an advertisement. From now on it is also stocked in a clinical channel, where a CGM can be ordered for a patient whose glucose needs monitoring.

That changes the buyer. Wellness is discretionary. It bends with price and with mood, and a large share of wellness purchases are abandoned within six weeks. Clinical need does not bend. It arrives with a diagnosis and a doctor who has reason to care whether the sensor stays on the arm through month three.

The market this reaches

By our estimate, medical hardware and curative care for metabolic illness is a USD 600 million market in Indonesia alone. Etana sells into it now.

That figure is the size of the market. It is not a projection of A1C revenue.

Why a pharmaceutical company wanted a software partner

Hardware is a commodity. Interpretation is not.

Nobody wears a sensor for ninety days because of the sensor. They wear it because it told them something worth knowing. Sally, the AI inside A1C, reads glucose against sleep debt, schedule, weather, and the meal that ran late because a meeting overran. Reorder rate is the whole economics of a sensor business, and interpretation drives reorder rate.

Metabolic disease is also where the pharmaceutical industry has committed the next decade. Eli Lilly became the first drug company worth more than a trillion dollars, on demand for GLP-1 medicines.

Disclosures: The USD 600 million figure is A1C's own estimate of market size, built from several third-party forecasts rather than a single published source. It is not a projection of A1C revenue. A1C Insights is not a diagnostic device and does not treat, cure, or prevent disease.